Pipeline: Overview

Allarity Therapeutics is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP^® companion diagnostic to select and treat patients most likely to benefit from treatment.

Allarity’s other clinical development activities

Allarity is also supporting development of a limited number of external programs.

Unless otherwise specified, all product and service name appearing in this internet site are trademark owned by or licensed to Allarity, its subsidiaries or affiliates. No use of any Allarity trademark, trade name, or trade dress in this site may be made without the prior written authorization of Allarity, except to identify the product or services of company.

United States:
24 School Street, 2nd Floor,
Boston, MA 02108
USA
Tel. +1 401-426-4664

Denmark:
Venlighedsvej 1
2970 Hoersholm
Denmark
Tel. +45 88 74 24 14
CVR: 34623562

Pipeline: Overview

Allarity Therapeutics is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP® companion diagnostic to select and treat patients most likely to benefit from treatment.

Allarity’s other clinical development activities

Allarity Therapeutics is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP^® companion diagnostic to select and treat patients most likely to benefit from treatment.